The REGENXBIO Manufacturing Innovation Center is a cGMP gene therapy facility expertly designed and built for the manufacturing of NAV Technology-based AAV vectors at scales suitable for commercial production.
This state-of-the-art facility, housed in the same building as our research, process development and clinical teams, allows us to accelerate the process of developing AAV Therapeutics for patients in need.
The REGENXBIO Manufacturing Innovation Center is built to meet global clinical and commercial regulatory standards, and makes REGENXBIO one of only a few gene therapy companies worldwide with a cGMP facility capable of production at scales up to 2,000 liters.
NAVXpress™ is REGENXBIO’s proprietary, high-yielding suspension-based manufacturing process. The NAVXpress platform has demonstrated robust scalability with consistent yield and product purity, both critically important factors for gene therapy manufacturing.